Cargando…

CSF Presenilin-1 complexes are increased in Alzheimer’s disease

BACKGROUND: Presenilin-1 (PS1) is the active component of the amyloid precursor protein cleaving γ-secretase complex. PS1 protein is a transmembrane protein containing multiple hydrophobic regions which presence in cerebrospinal fluid (CSF) has not been measured to date. This study assesses whether...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Ayllón, María-Salud, Campanari, María-Letizia, Brinkmalm, Gunnar, Rábano, Alberto, Alom, Jordi, Saura, Carlos A, Andreasen, Niels, Blennow, Kaj, Sáez-Valero, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893612/
https://www.ncbi.nlm.nih.gov/pubmed/24252417
http://dx.doi.org/10.1186/2051-5960-1-46
_version_ 1782299727881043968
author García-Ayllón, María-Salud
Campanari, María-Letizia
Brinkmalm, Gunnar
Rábano, Alberto
Alom, Jordi
Saura, Carlos A
Andreasen, Niels
Blennow, Kaj
Sáez-Valero, Javier
author_facet García-Ayllón, María-Salud
Campanari, María-Letizia
Brinkmalm, Gunnar
Rábano, Alberto
Alom, Jordi
Saura, Carlos A
Andreasen, Niels
Blennow, Kaj
Sáez-Valero, Javier
author_sort García-Ayllón, María-Salud
collection PubMed
description BACKGROUND: Presenilin-1 (PS1) is the active component of the amyloid precursor protein cleaving γ-secretase complex. PS1 protein is a transmembrane protein containing multiple hydrophobic regions which presence in cerebrospinal fluid (CSF) has not been measured to date. This study assesses whether PS1 and other components of the γ-secretase complex are present in CSF. RESULTS: Here, we show that PS1 is present in ventricular post-mortem and lumbar ante-mortem CSF, and plasma as 100–150-kDa hetero-complexes containing both the N- and C-terminal fragments (NTF and CTF) of the protein. Immunoprecipitation and immunoblotting with different antibodies confirmed the identity of the PS1 species. The γ-secretase components, APH-1 (anterior pharynx-defective 1) and PEN-2 (presenilin enhancer 2), as well as presenilin-2 (PS2) fragments, co-exist within these CSF complexes, while nicastrin is not detected. These CSF-PS1 complexes differ from active γ-secretase membrane-complexes, and may represent nonspecific aggregation of the PS1 protein. Levels of PS1 complexes are increased in CSF samples from autopsy-confirmed Alzheimer’s disease (AD) cases and were found to be more stable than complexes in CSF from control subjects. Despite similar levels of total PS1 in CSF from probable AD patients and cognitively normal subjects, an increased proportion of highly stable PS1 complexes were observed in AD CSF. CONCLUSIONS: Our data suggest that fragments of the PS1 protein present in CSF as complexes may be useful as a biomarker for AD.
format Online
Article
Text
id pubmed-3893612
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38936122014-01-17 CSF Presenilin-1 complexes are increased in Alzheimer’s disease García-Ayllón, María-Salud Campanari, María-Letizia Brinkmalm, Gunnar Rábano, Alberto Alom, Jordi Saura, Carlos A Andreasen, Niels Blennow, Kaj Sáez-Valero, Javier Acta Neuropathol Commun Research BACKGROUND: Presenilin-1 (PS1) is the active component of the amyloid precursor protein cleaving γ-secretase complex. PS1 protein is a transmembrane protein containing multiple hydrophobic regions which presence in cerebrospinal fluid (CSF) has not been measured to date. This study assesses whether PS1 and other components of the γ-secretase complex are present in CSF. RESULTS: Here, we show that PS1 is present in ventricular post-mortem and lumbar ante-mortem CSF, and plasma as 100–150-kDa hetero-complexes containing both the N- and C-terminal fragments (NTF and CTF) of the protein. Immunoprecipitation and immunoblotting with different antibodies confirmed the identity of the PS1 species. The γ-secretase components, APH-1 (anterior pharynx-defective 1) and PEN-2 (presenilin enhancer 2), as well as presenilin-2 (PS2) fragments, co-exist within these CSF complexes, while nicastrin is not detected. These CSF-PS1 complexes differ from active γ-secretase membrane-complexes, and may represent nonspecific aggregation of the PS1 protein. Levels of PS1 complexes are increased in CSF samples from autopsy-confirmed Alzheimer’s disease (AD) cases and were found to be more stable than complexes in CSF from control subjects. Despite similar levels of total PS1 in CSF from probable AD patients and cognitively normal subjects, an increased proportion of highly stable PS1 complexes were observed in AD CSF. CONCLUSIONS: Our data suggest that fragments of the PS1 protein present in CSF as complexes may be useful as a biomarker for AD. BioMed Central 2013-08-06 /pmc/articles/PMC3893612/ /pubmed/24252417 http://dx.doi.org/10.1186/2051-5960-1-46 Text en Copyright © 2013 García-Ayllón et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
García-Ayllón, María-Salud
Campanari, María-Letizia
Brinkmalm, Gunnar
Rábano, Alberto
Alom, Jordi
Saura, Carlos A
Andreasen, Niels
Blennow, Kaj
Sáez-Valero, Javier
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
title CSF Presenilin-1 complexes are increased in Alzheimer’s disease
title_full CSF Presenilin-1 complexes are increased in Alzheimer’s disease
title_fullStr CSF Presenilin-1 complexes are increased in Alzheimer’s disease
title_full_unstemmed CSF Presenilin-1 complexes are increased in Alzheimer’s disease
title_short CSF Presenilin-1 complexes are increased in Alzheimer’s disease
title_sort csf presenilin-1 complexes are increased in alzheimer’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893612/
https://www.ncbi.nlm.nih.gov/pubmed/24252417
http://dx.doi.org/10.1186/2051-5960-1-46
work_keys_str_mv AT garciaayllonmariasalud csfpresenilin1complexesareincreasedinalzheimersdisease
AT campanarimarialetizia csfpresenilin1complexesareincreasedinalzheimersdisease
AT brinkmalmgunnar csfpresenilin1complexesareincreasedinalzheimersdisease
AT rabanoalberto csfpresenilin1complexesareincreasedinalzheimersdisease
AT alomjordi csfpresenilin1complexesareincreasedinalzheimersdisease
AT sauracarlosa csfpresenilin1complexesareincreasedinalzheimersdisease
AT andreasenniels csfpresenilin1complexesareincreasedinalzheimersdisease
AT blennowkaj csfpresenilin1complexesareincreasedinalzheimersdisease
AT saezvalerojavier csfpresenilin1complexesareincreasedinalzheimersdisease